Kidney cancer drug given approval for NHS use for England

The drug, cabozantinib, can potentially turn off tumours and prolong the lives of patients with advanced kidney cancer.

Treatment options for kidney cancer are currently limited and according to the charity Kidney Research UK, the new drug would offer patients “more hope and more time with their loved ones”.

The drug works by targeting molecules on drug-resistant cancer cells, either stopping the tumours or putting them on hold. In recent trials, it was shown to benefit patients whose cancer had spread to other parts of the body and become resistant to other treatments.

A spokesperson from Kidney Research UK said “We are pleased to see cabozantinib has been approved by the National Institute for Health and Care Excellence, offering patients with renal cell carcinoma an increased chance of improved progression-free survival, compared to the standard therapy.”

Chadwick Lawrence’s specialist team of clinical negligence lawyers have years of experience in medical negligence compensation claims, and have obtained substantial compensation for our clients. Not only do we represent clients in Yorkshire, but because of our reputation we also represent clients nationally.

If you believe that you or a relative may have been injured as a result of clinical/medical negligence, please call for free legal advice from our medical negligence solicitors on the freephone number below.

Posted by Karen Motley, Paralegal, Clinical Negligence Department, Chadwick Lawrence LLP (karenmotley@chadlaw.co.uk), medical negligence lawyers and clinical negligence solicitors in Huddersfield, Leeds, Wakefield and Halifax, West Yorkshire.

Freephone : 0800 304 7382